SLTM Solta Medical, (MM)

HAYWARD, Calif., April 30 /PRNewswire-FirstCall/ -- Solta Medical, Inc. (NASDAQ:SLTM), a global leader in the medical aesthetics market, today announced that it has received regulatory clearance to market and sell Thermage(R) systems in China. "We are excited about the opportunity to market the premier non-invasive procedure for tightening and contouring skin in the People's Republic of China," said Stephen J. Fanning, Chairman of the Board, President and CEO of Solta Medical. "We have also applied for regulatory approvals in China for our Fraxel(R) products and expect upon approval that these products will allow us to address additional opportunities in the Chinese market." About Solta Medical, Inc. Solta Medical, Inc. is a global leader in the medical aesthetics market providing innovative, safe, and effective anti-aging solutions for patients which enhance and expand the practice of medical aesthetics for physicians. The company offers products to address aging skin under the industry's two premier brands: Thermage(R) and Fraxel(R). Thermage is an innovative, non-invasive radiofrequency procedure for tightening and contouring skin. As the leader in fractional laser technology, Fraxel delivers minimally invasive clinical solutions to resurface aging and sun damaged skin. Since 2002, over one million Thermage and Fraxel procedures have been performed in nearly 80 countries. Thermage and Fraxel are the perfect complement for any aesthetic practice. For more information about Solta Medical, call 877-782-2286 or log on to http://www.solta.com/. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause Solta Medical's actual results to differ materially from the statements contained herein. Further information on potential risk factors that could affect Solta Medical's business and its financial results are detailed in its Form 10-K for the year ended December 31, 2008, and other reports as filed from time to time with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, especially guidance on future financial performance, which speaks only as of the date they are made. Solta Medical undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events. CONTACT: Jack Glenn, Chief Financial Officer of Solta Medical, Inc., +1-510-786-6890; or investors, Doug Sherk, or Jenifer Kirtland, , both of EVC Group, +1-415-896-6820, for Solta Medical, Inc. Web Site: http://www.solta.com/ DATASOURCE: Solta Medical, Inc. CONTACT: Jack Glenn, Chief Financial Officer of Solta Medical, Inc., +1-510-786-6890; or investors, Doug Sherk or Jenifer Kirtland, , both of EVC Group, +1-415-896-6820, for Solta Medical, Inc. Web Site: http://www.solta.com/

Copyright